MSD
Keytruda success continues, beating Opdivo in lung cancer survival
April 17, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …
Keytruda continues success with new Phase 3 data in adjuvant melanoma
April 16, 2018Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer
MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …
Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression
April 10, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …
Keytruda combo fails at Phase 3 in metastatic melanoma
April 9, 2018Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure
Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …
Top Ten most popular articles on Pharmafile.com this week
March 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Cancer, GSK, Hemlibra, MSD, Roche, Sun Pharma, Takeda, brexit, pharma, tecentriq, top ten
As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …
Working Life: Chris Round, Head of EMEA Region, Merck KGaA
March 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Round, MSD, Merck, Merck KGaA, Working Life, pharma
Merck KGaA’s Chris Round, Head of EMEA Region, spoke with Pharmafile.com to discuss his time at both the US and …
NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy
March 16, 2018Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma
UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …
Ontruzant launches to become first Herceptin biosimilar available in the UK
March 8, 2018Sales and Marketing Cancer, Herceptin, MSD, Ontruzant, Roche, Samsung Bioepis, pharma
Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in …
Eisai and MSD team up to combine Lenvima and Keytruda in cancer
March 8, 2018Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …
MSD poised to acquire viral immuno-oncology firm Viralytics for $394m
February 21, 2018Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma
MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
Long-running, $2.5bn lawsuit swings in Gilead’s favour
February 19, 2018Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi
The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …
Biogen shares hit by key Alzheimer’s drug concerns
February 15, 2018Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical
Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …
New biotech facility to bring 350 jobs to Dublin
February 14, 2018Manufacturing and Production, Research and Development Dublin, Ireland, MSD, pharma
MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs …
MSD shuts down Phase 3 trial in prodromal Alzheimer’s
February 14, 2018Research and Development Alzheimer's, MSD, pharma, verubecestat
Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a …
EMA committee recommends seven therapies from Roche, GSK, MSD and more
January 29, 2018Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
